These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 765862)

  • 1. [Treatment of multiple sclerosis using immunosuppression. Critical discussion of results].
    Hommes OR
    Ned Tijdschr Geneeskd; 1976 Mar; 120(10):424-30. PubMed ID: 765862
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interaction of central nervous system local immunity and systemic immunity during multiple sclerosis].
    Tourtellotte WW
    Rev Neurol (Paris); 1972 Nov; 127(5):497-504. PubMed ID: 4588993
    [No Abstract]   [Full Text] [Related]  

  • 3. [IgG synthesis in the central nervous system in multiple sclerosis and other neurologic diseases. Measurement and validity].
    Safár J; Vymazal J; Tichý J; Růzicková V
    Cas Lek Cesk; 1985 Sep; 124(36):1131-6. PubMed ID: 4028102
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of treatment with Encorton (Polfa), Solu-Medrol and Encorton and Cyclophosphamide and Encorton on the production of immunoglobulin G in the central nervous system in multiple sclerosis].
    Ochudło S
    Wiad Lek; 1989 Dec; 41(23):1579-83. PubMed ID: 2669352
    [No Abstract]   [Full Text] [Related]  

  • 5. [Significance of increased immunoglobulin G levels in the cerebrospinal fluid of patients with multiple sclerosis].
    Out TA; van der Helm HJ
    Ned Tijdschr Geneeskd; 1984 Sep; 128(35):1666-8. PubMed ID: 6483038
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of the treatment with encorton (Polfa) on the production of immunoglobulin G in the central nervous system of patients with multiple sclerosis].
    Ochudło S
    Wiad Lek; 1987 Dec; 40(23):1588-92. PubMed ID: 3451587
    [No Abstract]   [Full Text] [Related]  

  • 7. [Function of the hemato-encephelic barrier and IgG synthesis in the central nervous system in multiple sclerosis and other neurologic disorders].
    Safár J; Vymazal J; Tichý J
    Cesk Neurol Neurochir; 1986 Nov; 49(6):382-9. PubMed ID: 3802248
    [No Abstract]   [Full Text] [Related]  

  • 8. The future of multiple sclerosis treatment.
    Cohen JA
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early immunosuppressive effect of parenteral methylprednisolone in the treatment of multiple sclerosis.
    Durelli L; Baggio GF; Bergamasco B; Barile C; Cocito D; Delsedime M; Perla F; Riccio A; Bergamini L
    Acta Neurol (Napoli); 1985; 7(3-4):338-44. PubMed ID: 3904340
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunosuppressive treatment in multiple sclerosis].
    Vermeulen M; Zegerius L; van Crevel H
    Ned Tijdschr Geneeskd; 1987 Jan; 131(3):93-6. PubMed ID: 3821989
    [No Abstract]   [Full Text] [Related]  

  • 12. [Initial experiences with the Reiber 1979 determination of autochthonous IgG production within the scope of clinical and immunologic follow-up studies in multiple sclerosis treated with immunosuppressive therapy].
    Dachsel R; Köppel C
    Psychiatr Neurol Med Psychol (Leipz); 1989 Jul; 41(7):420-5. PubMed ID: 2772076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunoglobulin G in cerebrospinal fluid of patients with multiple sclerosis. Study with immunosuppression. Preliminary report].
    Tavolato B
    Acta Neurol (Napoli); 1972; 27(2):121-2. PubMed ID: 4557555
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunosuppression: promises and failures.
    Oger J
    J Neurol Sci; 2007 Aug; 259(1-2):74-8. PubMed ID: 17382964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid immunoglobulins and the central nervous system as an immunological organ particularly in multiple sclerosis and subacute sclerosing panencephalitis.
    Tourtellotte WW
    Res Publ Assoc Res Nerv Ment Dis; 1971; 49():112-55. PubMed ID: 4107848
    [No Abstract]   [Full Text] [Related]  

  • 16. Central nervous system infections - a potential complication of systemic immunotherapy.
    Hemmer B; Frohman E; Hartung HP; Stüve O
    Curr Opin Neurol; 2006 Jun; 19(3):271-6. PubMed ID: 16702834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of multiple sclerosis--2. Application of a new immunological basic research is close].
    Svenningsson A; Andersson M; Olsson T
    Lakartidningen; 1998 Dec; 95(49):5631-5. PubMed ID: 9863301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunological abnormalities in multiple sclerosis].
    Tabira T
    No To Shinkei; 1983 Jun; 35(6):535-41. PubMed ID: 6194805
    [No Abstract]   [Full Text] [Related]  

  • 19. Quantitation of the synthesis of immunoglobulin G within the central nervous system.
    Whitaker JN
    Ann Neurol; 1985 Jan; 17(1):11-2. PubMed ID: 3985579
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple sclerosis: an overview.
    Rose AS
    Adv Neurol; 1981; 31():3-9. PubMed ID: 7325046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.